Heron Therapeutics Appoints Thomas Cusack to its Board
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company, has announced that Thomas Cusack is now part of its Board of Directors. This strategic decision is expected to enhance the company’s governance and provide valuable insights derived from Mr. Cusack's extensive experience in corporate finance and investment management.
Experience Highlights of Thomas Cusack
Mr. Cusack brings over 20 years of profound investment management expertise to Heron. Prior to joining the Board on October 27, 2025, he served as a Managing Director at Starboard Value LP for over a decade, a firm well-recognized for its proactive strategies in enhancing corporate performance. His leadership at Starboard Value significantly influenced many public companies, enabling them to refine operational strategies and invigorate corporate governance.
Background in Investment Banking
Before his tenure at Starboard Value, Mr. Cusack worked in investment banking with renowned firms such as Barclays Capital and Lehman Brothers. His focus during this phase was primarily on Mergers & Acquisitions, especially within the Technology, Media, and Telecommunications sectors. This broad yet focused investment background positions him uniquely at Heron, where strategic growth is paramount.
CEO's Perspective on the Appointment
Craig Collard, Chief Executive Officer at Heron Therapeutics, expressed his enthusiasm about the appointment, stating, "We are pleased to welcome Tom to Heron's Board of Directors. Tom will undoubtedly bring a wealth of perspective to benefit our efforts to build momentum at Heron." This collaboration signifies a commitment to enhancing the company's trajectory through informed governance.
About Heron Therapeutics, Inc.
Heron Therapeutics is dedicated to pioneering therapeutic innovations that simplify treatment processes and improve patient care. Its imperative to deliver effective solutions aligns with the company’s ambition to set new standards in acute care and oncology through their innovative therapies. The company aims to leverage advanced science and patented technologies in its drug discovery ventures.
Commitment to Innovation
Heron Therapeutics focuses on ensuring that their therapeutic product portfolio not only meets current medical needs but also anticipates future challenges faced by healthcare professionals and patients alike. The ongoing development of these products aims to reshape medical practices and enhance the standard of care.
Media Contact
For inquiries regarding Heron Therapeutics, please reach out to:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
Email: iduarte@herontx.com
Phone: 858-251-4400
Frequently Asked Questions
What is the role of Thomas Cusack at Heron Therapeutics?
Thomas Cusack has been appointed to the Board of Directors, where he will contribute his extensive experience in corporate finance and investment management.
Why is Heron Therapeutics appointing new board members?
The appointment of new board members like Thomas Cusack is part of Heron’s strategy to enhance corporate governance and improve overall performance.
What are Heron Therapeutics' main focus areas?
Heron Therapeutics focuses on developing and commercializing therapeutic innovations centered on improving patient care in the fields of acute care and oncology.
How does Thomas Cusack's background benefit Heron?
His strong background in investment management and corporate governance will assist in strategic decision-making that aims to propel the company’s growth.
Where can I find more information about Heron Therapeutics?
For detailed information, you can visit www.herontx.com.
